Company intelligence / Profile preview

CVasThera

Toulouse, Occitanie, Francecvasthera.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CVasThera is focused on accelerating innovation in early-stage drug development for cardiovascular and bowel diseases. The company has received grants and government recognition for its R&D capabilities in France. Its lead program includes a candidate for Crohn’s disease currently supported by regional funding and academic collaboration with INSERM Toulouse. Another program involves expertise provided to OP2drugs relating to the OP2113 program targeting acute myocardial infarction at the pre-clinical stage.

Therapeutic areas: GastroenterologyCardiovascular
Modalities: Small molecules (e.g., CVT12011965 for Crohn's disease)
Industry: Biotech

Drug pipeline

1 asset

CVT12011965

Unknown

Partnerships

OP2drugs (collaboration on the OP2113 program)

Beyond the preview

Go deeper on CVasThera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVasThera.

Explore the full profile